Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 15-16/2015

01.08.2015 | original article

Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients

verfasst von: Julian Ananiev, PhD, Elina Aleksandrova, Desislava Skerleva, MD, Maya Gulubova, MD, PhD, Anastasiya Chokoeva, Prof. Dr. Torello Lotti, MD, MD (Hon), Prof. Dr. Uwe Wollina, Georgi Tchernev, MD, PhD, Milica Kontić, MD, Jelena Stojšić, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2015

Einloggen, um Zugang zu erhalten

Summary

The aim of the study was to assess the expression and significance of HER2 and HER3, and Ile/Val single nucleotide polymorphism (SNP) of HER2 in lung cancer patients. Thirty seven cases of lung cancer were investigated immunohistochemically for HER2 and HER3 expression. PCR followed by restriction fragment length polymorphism (RFLP) was used to analyze the presence of HER-2 SNP at codon 655 in 20 samples. The results were compared with clinical and pathological parameters of investigated patients.
We found that 100 % of the cases were negative for HER2, 29.7 % were with moderate or strong HER3 expression and 70.3 % of the tumors—without or with low expression for HER3. Lymph node metastasis were found in 40 % of HER3 positive cases (χ2 = 4.752; p = 0.029). Moderately-differentiated tumors do not express neither of investigated markers (χ2 = 6.719; p = 0.035). HER2 RFLP—PCR analysis showed genotype AG in five patients (25 %) and the rest of 15 cases (75 %) had АА (Ile/Ile) genotype. Patients with metastasis had genotype АА (Ile/Ile) in 80 % and genotype AG (Ile/Val) in 20 % (χ2 = 2.857; p = 0.091).
Our results indicate that SNP in HER2 codon 655 and investigation of HER2 and HER3 expression could be helpful to outline the prognosis for patients with lung adenocarcinoma.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
Zurück zum Zitat Colby TV, Koss M, Travis WD. Tumors of the lower respiratory tract. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1995. Colby TV, Koss M, Travis WD. Tumors of the lower respiratory tract. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1995.
3.
Zurück zum Zitat Melville A, Eastwood A. Management of lung cancer. Qual Health Care. 1998;7(3):17 0–7.CrossRef Melville A, Eastwood A. Management of lung cancer. Qual Health Care. 1998;7(3):17 0–7.CrossRef
4.
Zurück zum Zitat Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 2004;101(1):3–27.PubMedCrossRef Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 2004;101(1):3–27.PubMedCrossRef
5.
Zurück zum Zitat Yousem SA. Role of molecular studies in the diagnosis of lung adenocarcinoma. Mod Pathol. 2012;25 Suppl 1:S11–7.PubMedCrossRef Yousem SA. Role of molecular studies in the diagnosis of lung adenocarcinoma. Mod Pathol. 2012;25 Suppl 1:S11–7.PubMedCrossRef
6.
Zurück zum Zitat Satiroglu-Tufan NL, Bir F, Calli-Demirkan N. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol. 2006;12(20):3283–7.PubMedCentralPubMed Satiroglu-Tufan NL, Bir F, Calli-Demirkan N. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol. 2006;12(20):3283–7.PubMedCentralPubMed
7.
Zurück zum Zitat Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3–S8.PubMedCrossRef Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3–S8.PubMedCrossRef
8.
Zurück zum Zitat Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):15–31.PubMedCentralPubMedCrossRef Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):15–31.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRef Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRef
10.
Zurück zum Zitat Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 2002;7:376–89.CrossRef Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 2002;7:376–89.CrossRef
11.
Zurück zum Zitat Zhou B, Liao Y, Xia W, Spohn B, Lee M, Hung M. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3:245–52.PubMedCrossRef Zhou B, Liao Y, Xia W, Spohn B, Lee M, Hung M. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001;3:245–52.PubMedCrossRef
12.
Zurück zum Zitat Zhou B, Liao Y, Xia W, Zou Y, Spohn B, Hung M. HER2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3:973–82.PubMedCrossRef Zhou B, Liao Y, Xia W, Zou Y, Spohn B, Hung M. HER2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3:973–82.PubMedCrossRef
13.
Zurück zum Zitat Kiyokawa N, Karunagaran D, Lee E, Xie Y, Yan D, Hung M. Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu. Oncogene. 1997;15:2633–41.PubMedCrossRef Kiyokawa N, Karunagaran D, Lee E, Xie Y, Yan D, Hung M. Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu. Oncogene. 1997;15:2633–41.PubMedCrossRef
14.
Zurück zum Zitat Landi L, Cappuzzo F. HER2 and lung cancer. Expert Rev Anticancer Ther. 2013;13(10):1219–28.PubMedCrossRef Landi L, Cappuzzo F. HER2 and lung cancer. Expert Rev Anticancer Ther. 2013;13(10):1219–28.PubMedCrossRef
16.
17.
Zurück zum Zitat Dahabreh IJ, Murray S. Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2011;35(6):503–9.PubMedCrossRef Dahabreh IJ, Murray S. Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2011;35(6):503–9.PubMedCrossRef
18.
Zurück zum Zitat Kruszyna Ł, Lianeri M, Roszak A, Jagodziński PP. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clin Biochem. 2010;43(6):545–8.PubMedCrossRef Kruszyna Ł, Lianeri M, Roszak A, Jagodziński PP. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clin Biochem. 2010;43(6):545–8.PubMedCrossRef
19.
Zurück zum Zitat Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun. 2005;335(4):1173–8.PubMedCrossRef Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun. 2005;335(4):1173–8.PubMedCrossRef
20.
Zurück zum Zitat Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001;7(10):3239–50.PubMed Bunn PA Jr, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001;7(10):3239–50.PubMed
21.
Zurück zum Zitat Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002;29(1 Suppl 4):51–8.PubMedCrossRef Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002;29(1 Suppl 4):51–8.PubMedCrossRef
22.
Zurück zum Zitat Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S, et al. The prognostic significance of HER2 overexpression in NSCLC. Anticancer Res. 2011;31(12):4631–6.PubMed Takenaka M, Hanagiri T, Shinohara S, Kuwata T, Chikaishi Y, Oka S, et al. The prognostic significance of HER2 overexpression in NSCLC. Anticancer Res. 2011;31(12):4631–6.PubMed
23.
Zurück zum Zitat Calikusu Z, Yildirim Y, Akcali Z, Sakalli H, Bal N, Unal I, et al. The effect of HER2 expression on cisplatin-based chemotherapy in advanced NSCLC patients. J Exp Clin Cancer Res. 2009;28:97.PubMedCentralPubMedCrossRef Calikusu Z, Yildirim Y, Akcali Z, Sakalli H, Bal N, Unal I, et al. The effect of HER2 expression on cisplatin-based chemotherapy in advanced NSCLC patients. J Exp Clin Cancer Res. 2009;28:97.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH, Eastern Cooperative Oncology Group Study 2598. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004;22(7):1180–7.PubMedCrossRef Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH, Eastern Cooperative Oncology Group Study 2598. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004;22(7):1180–7.PubMedCrossRef
25.
Zurück zum Zitat Bellezza G, Del Sordo R, Colella R, Ludovini V, Ragusa M, Bianconi F, et al. Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). Virchows Arch. 2013;463(5):663–71.PubMedCrossRef Bellezza G, Del Sordo R, Colella R, Ludovini V, Ragusa M, Bianconi F, et al. Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). Virchows Arch. 2013;463(5):663–71.PubMedCrossRef
26.
Zurück zum Zitat Xu JM, Han Y, Duan HQ, Gao EM, Zhang Y, Liu XQ, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced NSCLC patients treated with gefitinib. J Cancer Res Clin Oncol. 2009;135(6):771–82.PubMedCrossRef Xu JM, Han Y, Duan HQ, Gao EM, Zhang Y, Liu XQ, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced NSCLC patients treated with gefitinib. J Cancer Res Clin Oncol. 2009;135(6):771–82.PubMedCrossRef
27.
Zurück zum Zitat Bellezza G, Del Sordo R, Colella R, Ludovini V, Ragusa M, Bianconi F, et al. Co-expression of receptors of the HER family correlates with clinical outcome in NSCLC (NSCLC). Virchows Arch. 2013;463(5):663–71.PubMedCrossRef Bellezza G, Del Sordo R, Colella R, Ludovini V, Ragusa M, Bianconi F, et al. Co-expression of receptors of the HER family correlates with clinical outcome in NSCLC (NSCLC). Virchows Arch. 2013;463(5):663–71.PubMedCrossRef
28.
29.
Zurück zum Zitat Wang L, Habuchi T, Takahashi T, Kamoto T, Zuo T, Mitsumori K, et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer. 2002;97(6):787–90.PubMedCrossRef Wang L, Habuchi T, Takahashi T, Kamoto T, Zuo T, Mitsumori K, et al. No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer. 2002;97(6):787–90.PubMedCrossRef
Metadaten
Titel
Impact of HER2 codon 655 polymorphism and expression of HER2 and HER3 in non small cell lung cancer patients
verfasst von
Julian Ananiev, PhD
Elina Aleksandrova
Desislava Skerleva, MD
Maya Gulubova, MD, PhD
Anastasiya Chokoeva
Prof. Dr. Torello Lotti, MD, MD (Hon)
Prof. Dr. Uwe Wollina
Georgi Tchernev, MD, PhD
Milica Kontić, MD
Jelena Stojšić, MD
Publikationsdatum
01.08.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0366-5

Weitere Artikel der Ausgabe 15-16/2015

Wiener Medizinische Wochenschrift 15-16/2015 Zur Ausgabe